Industries > Pharma > Liquid Biopsy Market Report 2020-2030

Liquid Biopsy Market Report 2020-2030

Forecasts by Product (Instruments, Kits & Reagents, Services), by Sample Type (Blood Samples, Urine Samples, Others), by Biomarker (Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Others), by Cancer Type (Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Others), by End-user (Hospitals, Diagnostic Laboratories, Academic Institutions, Cancer Research Centres), by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa), Plus Analysis of Leading Companies

PUBLISHED: 09 June 2020
PAGES: 462
PRODUCT CODE: PHA0782
SUBMARKET: Diagnostics

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0782 Categories: , Tag:

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities to the key players in the near future.

This Visiongain report covers the global liquid biopsy market, including analysis of the market by product type, biomarker type, sample type, cancer type, end user and national markets for liquid biopsy products. We aim to provide a comprehensive and critical analysis of the market, assessing the market’s potential from a variety of viewpoints. We examine the opportunities and challenges that exist within the market, as well as the major commercial trends. We also analyses the market prospects for different segments and provide an overview of the research and development in this sector.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

Liquid Biopsy Market Dynamics:
• Increasing Prevalence of Cancer
• Rising Ageing Population
• Rising Demand for Safe and Minimally Invasive Procedures
• Advantages of Liquid Biopsy and Cost Effectiveness
• Disparity in Reimbursements
• Strict Regulatory Environment
• Increasing involvement of global market players through collaborations/agreements
• Progress in the development of liquid biopsy tests

Liquid Biopsy Market Segmentation 2020-2030:

Segmentation by Product, 2020 – 2030 (USD Million)
• Instruments
• Kits & Reagents
• Services

Segmentation by Sample Type, 2020 – 2030 (USD Million)
• Blood Samples
• Urine Samples
• Others

Segmentation by Biomarker, 2020 – 2030 (USD Million)
• Circulating Tumour Cell (CTC)
• Circulating Tumour DNA (ctDNA)
• Exosomes
• Others

Segmentation by Cancer Type, 2020 – 2030 (USD Million)
• Breast Cancer
• Colorectal Cancer
• Liver Cancer
• Lung Cancer
• Prostate Cancer
• Others

Segmentation by End-User, 2020 – 2030 (USD Million)
• Hospitals
• Diagnostic Laboratories
• Academic Institutions
• Cancer Research Centres

Segmentation by Geography, 2020 – 2030 (USD Million)

• North America
• U.S.
• Canada

• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Southeast Asia
• Rest of Asia Pacific

• Latin America
• Brazil
• Argentina
• Venezuela
• Mexico
• Rest of Latin America

• Middle East & Africa
• Turkey
• UAE
• South Africa
• Saudi Arabia
• Rest of Middle East & Africa

Liquid Biopsy Market Report 2020-2030

Liquid Biopsy Market: Top 10 Companies
• Menarini Silicon Biosystems, Inc.
• MDxHealth SA
• Biocept, Inc.
• Trovagene, Inc.
• Sysmex Inostics GmbH
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Liquid Biopsy Market Report 2020-2030: Forecasts by Product (Instruments, Kits & Reagents, Services), by Sample Type (Blood Samples, Urine Samples, Others), by Biomarker (Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Others), by Cancer Type (Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Others), by End-user (Hospitals, Diagnostic Laboratories, Academic Institutions, Cancer Research Centres), by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa), Plus Analysis of Leading Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Liquid Biopsy Market Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Liquid Biopsy Market Report 2020-2030


Latest Pharma news

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

READ

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

READ

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

READ

Visiongain Publishes Antibody Drug Conjugates Market Report 2022-2032

The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

28 November 2022

READ